UCB SA (OTCMKTS:UCBJF) Receives Consensus Recommendation of “Buy” from Analysts

UCB SA (OTCMKTS:UCBJF) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation.

Several equities analysts recently weighed in on UCBJF shares. Wolfe Research started coverage on UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research note on Monday, February 16th. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a research note on Thursday, January 15th.

UCB Price Performance

UCBJF opened at $280.85 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business has a 50 day simple moving average of $299.95 and a 200-day simple moving average of $295.42. UCB has a 12 month low of $168.65 and a 12 month high of $345.39.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.